Moderna Marches First Coronavirus Vaccine To US Test
Enters Clinic In Just 42 days
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The French drugmaker has joined the likes of Moderna, BioNTech and CureVac in advancing an mRNA vaccine against the virus that causes COVID-19 that could take the fraction of the time to develop compared with the old egg- and cell-based technology.